Page last updated: 2024-12-05

sulfapyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sulfapyridine is a sulfonamide antibiotic that was first synthesized in the 1930s. It was originally used to treat bacterial infections, but it was later found to be effective in treating ulcerative colitis. Sulfapyridine works by inhibiting the growth of bacteria. It is thought to be effective in treating ulcerative colitis because it reduces inflammation in the gut. Sulfapyridine is typically taken by mouth, but it can also be given intravenously. It is generally well-tolerated, but it can cause side effects such as nausea, vomiting, and diarrhea. Sulfapyridine is still used to treat ulcerative colitis today. It is often used in combination with other medications, such as corticosteroids. It is a common subject of research as it is believed to be effective in treating ulcerative colitis and other inflammatory bowel diseases. It is also being studied as a potential treatment for other conditions, such as rheumatoid arthritis.'

Sulfapyridine: Antibacterial, potentially toxic, used to treat certain skin diseases. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sulfapyridine : A sulfonamide consisting of pyridine with a 4-aminobenzenesulfonamido group at the 2-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5336
CHEMBL ID700
CHEBI ID132842
SCHEMBL ID44219
MeSH IDM0020757

Synonyms (214)

Synonym
BB 0258406
UPCMLD0ENAT5889155:001
BRD-K41406082-001-05-5
nsc4753
septipulmon
eubasin
haptocil
m+b 693
pyriamid
pyridazol
n(sup 1)-2-pyridylsulfanilamide
eubasinum
sulfanilamide, n(sup 1)-2-pyridyl-
sulfanilamide, n1-2-pyridyl-
benzenesulfonamide, 4-amino-n-2-pyridinyl-
sulfidin
thioseptal
a-499
m + b 693
piridazol
2-sulfanilylaminopyridine
coccoclase
n(sup1)-pyridylsulfanilamide
144-83-2
sulphapyridine
dagenan
sulfapyridine
nsc-4753
2-sulfanilamidopyridine
streptosilpyridine
trianon
ronin
plurazol
wln: t6nj bmswr dz
2-sulfapyridine
sulfidine
relbapiridina
adiplon
nsc-41791
nsc41791
DIVK1C_000216
KBIO1_000216
SPECTRUM_000996
PRESTWICK_1015
NCGC00016408-01
cas-144-83-2
OPREA1_344996
PRESTWICK3_000762
4-amino-n-2-pyridinylbenzenesulfonamide
4-amino-n-(2-pyridyl)benzenesulfonamide
BPBIO1_000886
BSPBIO_003265
IDI1_000216
BSPBIO_000804
4-amino-n-pyridin-2-ylbenzenesulfonamide
AO-801/41077453 ,
AB00052100
nsc 41791
m&b 693
sulfapiridina [inn-spanish]
2-sulfanilyl aminopyridine
sulfapyridinum [inn-latin]
sulphapyridin
ai3-01049
n1-2-pyridylsulfanilamide
solfapiridina [dcit]
benzenesulfonamide, 4-amino-n-(2-pyridinyl)-
2-sulfanilamidopyridin [german]
einecs 205-642-7
nsc 4753
2-(p-aminobenzenesulphonamido)pyridine
4-[(2-pyridylamino)sulfonyl]aniline
n(1)-2-pyridylsulfanilamide
n(1)-pyridylsulfanilamide
n-2-pyridylsulfanilamide
4-(2-pyridinylsulfonyl)aniline
DB00891
4-amino-n,2-pyridinylbenzenesulfonamide
4-amino-n-pyridin-2-yl-benzenesulfonamide
4-amino-n-(pyridin-2-yl)benzenesulfonamide
STK292439
sulfapyridine (usp/inn)
sulfapyridine (tn)
D02434
SPECTRUM5_001182
PRESTWICK2_000762
NCGC00022008-03
MLS000069725 ,
smr000058213
KBIO2_001476
KBIOGR_000751
KBIO2_006612
KBIOSS_001476
KBIO3_002766
KBIO2_004044
SPBIO_002743
SPECTRUM4_000346
PRESTWICK0_000762
SPECTRUM2_001323
SPBIO_001445
SPECTRUM3_001773
PRESTWICK1_000762
NINDS_000216
SPECTRUM1500551
NCGC00016408-02
NCGC00022008-04
sulfapyridinum
sulfapiridina
solfapiridina
CHEBI:132842 ,
2-sulfanilamidopyridin
HMS2092K05
inchi=1/c11h11n3o2s/c12-9-4-6-10(7-5-9)17(15,16)14-11-3-1-2-8-13-11/h1-8h,12h2,(h,13,14)
gechumimrbomgk-uhfffaoysa-
CHEMBL700
HMS500K18
n'-2-pyridylsulfanilide
2-(4-aminobenzenesulfonamido)pyridine
HMS1921C03
HMS1570I06
AKOS000121424
4-amino-n-(2-pyridinyl)benzenesulfonamide
A808279
4-azanyl-n-pyridin-2-yl-benzenesulfonamide
HMS2097I06
nsc-757329
pharmakon1600-01500551
nsc757329
dtxcid206067
dtxsid3026067 ,
tox21_110426
4-amino-n-2-pyridinyl-benzenesulfonamide
HMS2233H20
CCG-39261
NCGC00016408-03
NCGC00016408-05
NCGC00016408-04
NCGC00016408-06
m and b 693
FT-0674744
sulfapyridine [usp:inn:ban]
unii-y5v2n1ke8u
ec 205-642-7
y5v2n1ke8u ,
FT-0631839
NCGC00016408-10
SFY ,
EPITOPE ID:122235
S1617
HMS3372N13
sulfapyridine [orange book]
sulfapyridine [inn]
sulfapyridine [mi]
sulfapyridine [usp-rs]
sulfapyridine [usp impurity]
sulfapyridine [who-dd]
sulfapyridine [usp monograph]
sulfasalazine impurity j [ep impurity]
sulfapyridine [mart.]
sulfapyridine melting point standard
CS-2157
HY-B0212
SCHEMBL44219
tox21_110426_1
NCGC00016408-09
HS-0063
4-amino-n-(pyrimidin-2-yl) benzenesulfonamide (sulfadiazine) (14)
cid_5336
bdbm39340
W-108148
2-(p-aminobenzenesulfonamido)pyridine
AC-26818
sulfanilamide, n1-2(1h)-pyridylidene-
m&b-693
4-(2-pyridinylsulfonyl)aniline #
AB00052100_14
AB00052100_15
4-amino-n-(pyridin-2-yl)benzene-1-sulfonamide
mfcd00038036
SR-01000000207-2
sr-01000000207
sulfapyridine, united states pharmacopeia (usp) reference standard
sulfapyridine melting point standard, united states pharmacopeia (usp) reference standard
sulfapyridine, vetranal(tm), analytical standard
sulfapyridine melting point standard, pharmaceutical secondary standard; certified reference material
sulfapyridine, european pharmacopoeia (ep) reference standard
sulfapyridine, >=99.0%
SR-01000000207-3
SBI-0051525.P003
HMS3714I06
Q3976827
gtpl12698
sulfapyridine (dagenan)
sulfapyridine-13c6
BRD-K41406082-001-09-7
EN300-21145
sulfapyridine iii
4-amino-n-(1,2-dihydropyridin-2-ylidene)benzenesulfonamide
sulfapyridine 1000 microg/ml in acetonitrile
a 499
sulfapyridine (usp impurity)
sulfapyridinum (inn-latin)
sulfapyridine (usp-rs)
sulfasalazine impurity j (ep impurity)
sulfapyridin
sulfapyridine (usp:inn:ban)
sulfapiridina (inn-spanish)
sulfapyridine (mart.)
n1-2(1h)-pyridylidenesulfanilamide
4-((2-pyridylamino)sulfonyl)aniline
m&b693
sulfapyridine (usp monograph)
j01eb04
Z104492884

Research Excerpts

Overview

Sulfapyridine is a sulfonamide drug with antibacterial, antithyroid and antidiabetic properties.

ExcerptReferenceRelevance
"Sulfapyridine is a sulfonamide drug with antibacterial, antithyroid and antidiabetic properties."( Polymorph IV of 4-amino-N-2-pyridinylbenzenesulfonamide (sulfapyridine).
Bernstein, J, 1988
)
1.24

Toxicity

ExcerptReferenceRelevance
" To determine if there is an adverse effect in females, 20 mature Sprague-Dawley rats were assigned to a treatment (400 mg/kg sulphapyridine daily), or a control group."( Adverse effects of the salazopyrine metabolite sulphapyridine on female fertility in the rat.
Cheang, M; Jerome, J; Johnson, K; Kredentser, JV; McCoshen, JA,
)
0.13
"5%) had adverse effects that led to discontinuation of therapy in 14 (11."( Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.
Levy, M; Rachmilewitz, D; Rahav, G; Zylber-Katz, E, 1990
)
0.53
" This suggests that, at least in some patients, the adverse effects of sulfasalazine are due to 5-aminosalicylic acid rather than sulfapyridine."( Adverse effects with oral 5-aminosalicyclic acid.
Fardy, JM; Lloyd, DA; Reynolds, RP, 1988
)
0.48
" NAT2 activity has been diagnosed by phenotyping, that is, evaluating plasma concentrations or urinary excretions of tentatively administered test drugs for dose individualization and avoidance of serious adverse events."( N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events.
Aoyama, N; Gobara, M; Hatanaka, H; Kasuga, M; Kita, T; Komada, F; Okumura, K; Sakaeda, T; Sakai, T; Tanigawara, Y, 2002
)
0.58
" Toxicity assays by Vibrio fischeri proved that the transformation products were more toxic than the parent compound."( Photodegradation of sulfapyridine under simulated sunlight irradiation: kinetics, mechanism and toxicity evolvement.
Guo, C; Hao, Z; He, Y; Meng, W; Xu, J; Zhang, Y, 2014
)
0.73

Pharmacokinetics

Population pharmacokinetic modeling of paracetamol and sulfapyridine provides a suitable preclinical non-invasive experimental method for quantifying drug- and food-induced changes in the rate of GE and SITT.

ExcerptReferenceRelevance
" coli and pharmacokinetic studies presented, the suggested dose for the combination 2-sulfa-4,5-dimethyl-oxazole/TMP seems to be sufficient, the dosage regimen is correct, whereas the amount of 3-sulfa-5-methyl-isoxazole (SMZ) in the dose proposed for the combination SMZ/TMP seems to be unreasonably high and the dosage scheme is incorrect."( [Studies on synergistic behaviour and pharmacokinetics of the combination sulfonamide/trimethoprim. IV. A comparative study on potentiating the trimethoprim effect by various sulfonamides and critical observations on its dosing (author's transl)].
Seydel, JK; Wempe, E, 1977
)
0.26
"The pharmacokinetic disposition of sulfasalazine and its metabolites was studied in 8 young and 12 elderly patients with active rheumatoid arthritis."( The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis.
McDermott, BJ; Roberts, SD; Taggart, AJ, 1992
)
0.28
" Sulphasalazine itself is poorly absorbed (3 to 12%) and its elimination half-life of about 5 to 10 hours is probably affected by the absorption process."( Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
Klotz, U,
)
0.13
" The elimination half-life of sulphasalazine was prolonged in the elderly whilst renal clearance was increased in slow acetylators at 'steady-state'."( The pharmacokinetics of sulphasalazine in young and elderly patients with rheumatoid arthritis.
Ahnfelt, NO; Delargy, M; Elborn, S; Forbes, J; McDermott, B; Roberts, SD; Taggart, AJ, 1987
)
0.27
" Pharmacokinetic parameters, such as elimination rate constant (ke), clearance (Cl), and protein-binding constant (Kassoc), have been determined in rats."( Quantitative structure-pharmacokinetic relationships derived on antibacterial sulfonamides in rats and its comparison to quantitative structure-activity relationships.
Cordes, HP; Malyusz, M; Seydel, JK; Trettin, D; Wassermann, O, 1980
)
0.26
" Coadministration of zileuton did not significantly affect the area under the plasma concentration-time curve, the maximum (Cmax) or minimum (Cmin) plasma concentration and the time to Cmax of SASP, SP or ASP."( The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine.
Awni, WM; Braeckman, RA; Dubé, LM; Granneman, GR; Locke, CS, 1995
)
0.5
" We investigated the effects of genetic polymorphism of NAT2 on pharmacokinetic profiles of SASP and its two metabolites, sulfapyridine (SP) and N-acetylsufapyridine (AcSP)."( Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population.
Cao, XM; Li, JH; Liu, CG; Ma, JJ; Sun, SL; Yao, X, 2009
)
0.56
" After taking 1000mg SASP tablets, the plasma concentrations of SASP, SP and AcSP were measured with HPLC method and pharmacokinetic parameters were calculated by using the computing program 3P97."( Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population.
Cao, XM; Li, JH; Liu, CG; Ma, JJ; Sun, SL; Yao, X, 2009
)
0.35
"The AUC(0)(-)(72) and Cmax of SP in m/m subjects were significantly higher than those in w/m and w/w subjects, with the values of 172."( Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population.
Cao, XM; Li, JH; Liu, CG; Ma, JJ; Sun, SL; Yao, X, 2009
)
0.35
" This study aimed to investigate the feasibility of population pharmacokinetic modeling to quantify the rate of gastric emptying (GE) and small intestinal transit time (SITT) in response to drugs that affect GI motility in fed and fasted dogs."( Using pharmacokinetic modeling to determine the effect of drug and food on gastrointestinal transit in dogs.
Al-Saffar, A; Sjödin, L; Visser, S,
)
0.13
" Population pharmacokinetic analysis of paracetamol and sulfapyridine in plasma was used to determine the rate of GE and SITT."( Using pharmacokinetic modeling to determine the effect of drug and food on gastrointestinal transit in dogs.
Al-Saffar, A; Sjödin, L; Visser, S,
)
0.38
"Population pharmacokinetic modeling of paracetamol and sulfapyridine provides a suitable preclinical non-invasive experimental method for quantification of drug- and food-induced changes in the rate of GE and SITT in conscious beagle dogs for use in safety evaluations to predict changes in GI transit and/or to explain the pharmacokinetic profile of drugs under development."( Using pharmacokinetic modeling to determine the effect of drug and food on gastrointestinal transit in dogs.
Al-Saffar, A; Sjödin, L; Visser, S,
)
0.38
"Transporter gene knockout rats are practically advantageous over murine models for pharmacokinetic and excretion studies, but their phenotypic characterization is lacking."( Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
Bao, JQ; Bedwell, DW; Higgins, JW; Zamek-Gliszczynski, MJ, 2012
)
0.38

Bioavailability

Butanol reduced the rate of absorption of sulfapyridine but did not significantly affect the absorption rates of prednisolone or salicylic acid.

ExcerptReferenceRelevance
" Butanol reduced the rate of absorption of sulfapyridine but did not significantly affect the absorption rates of prednisolone or salicylic acid."( Effects of normal alcohols on intestinal absorption of salicylic acid, sulfapyridine, and prednisolone in rats.
Hayton, WL, 1975
)
0.75
" The extent of bioavailability of nitrofurantoin gave correlations with both gastric emptying time and small intestinal transit time."( [Gastrointestinal absorption of nitrofurantoin: evaluation of a newly developed method for determination of the gastrointestinal transit time in dogs].
Ikeda, Y; Kawazoe, Y; Mizuta, H; Ogawa, K, 1991
)
0.28
" Sulphasalazine itself is poorly absorbed (3 to 12%) and its elimination half-life of about 5 to 10 hours is probably affected by the absorption process."( Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
Klotz, U,
)
0.13
" There is no change in the rate of absorption of the release sulphapyridine."( Azo reduction of sulphasalazine in healthy volunteers.
Day, J; Houston, JB; Walker, J, 1982
)
0.26
" It was concluded that the presence of bran in the regimen strongly increases the intestinal absorption of chloramphenicol palmitate, with the lowest rate of absorption on standard concentrates, and it is tempting to speculate that this increase is due to a more rapid intestinal hydrolysis by an increased pancreatic lipase activity on bran."( Influence of bran on bioavailability of chloramphenicol administered orally to pigs.
Alvinerie, M; Bardon, T; Buéno, L; Fioramonti, J, 1984
)
0.27
" dapsone, nimesulide and sulphapyridine, have the potential to reduce the bioavailability of neutrophil-derived HOCl and, in turn, to favour the alpha 1-antitrypsin-dependent control of neutrophil elastolytic activity."( Sulphonamides as anti-inflammatory agents: old drugs for new therapeutic strategies in neutrophilic inflammation?
Balbi, A; Bevilacqua, M; Dallegri, F; Dapino, P; Ottonello, L; Scirocco, MC, 1995
)
0.29
"In two bioavailability studies performed under comparable conditions with 24 healthy subjects of both genders equally distributed, plasma levels of SP and acetylsulfapyridine (Ac-SP) were determined after oral intake of enteric coated formulations of sulfasalazine (500 mg and 1,000 mg, respectively)."( Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics.
Anschütz, M; Blume, HH; Hippius, M; Kuhn, UD; Schmücker, K; Schug, BS, 2010
)
0.56
" In Mdr1a knockout rats, loperamide and paclitaxel oral bioavailability was 2- and 4-fold increased, respectively, whereas clearance was significantly reduced (40-42%), consistent with the expected 10- to 20-fold reduction in paclitaxel excretion."( Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
Bao, JQ; Bedwell, DW; Higgins, JW; Zamek-Gliszczynski, MJ, 2012
)
0.38
"Amphotericin B (AmB) is poorly absorbed from the gastrointestinal tract."( Effect of Food Status on the Gastrointestinal Transit of Amphotericin B-Containing Solid Lipid Nanoparticles in Rats.
Amekyeh, H; Billa, N; Lim, SC; Yuen, KH, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" A single study of serum can determine acetylator phenotype in patients on sulfasalazine therapy without using any other drug for this purpose and may help ascertain dosage and assess side effects."( Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease.
Das, KM; Eastwood, MA, 1975
)
0.55
" coli and pharmacokinetic studies presented, the suggested dose for the combination 2-sulfa-4,5-dimethyl-oxazole/TMP seems to be sufficient, the dosage regimen is correct, whereas the amount of 3-sulfa-5-methyl-isoxazole (SMZ) in the dose proposed for the combination SMZ/TMP seems to be unreasonably high and the dosage scheme is incorrect."( [Studies on synergistic behaviour and pharmacokinetics of the combination sulfonamide/trimethoprim. IV. A comparative study on potentiating the trimethoprim effect by various sulfonamides and critical observations on its dosing (author's transl)].
Seydel, JK; Wempe, E, 1977
)
0.26
"The disposition kinetics and dosage regimen of sulfapyridine were studied in buffalo calves following a single intravenous dose of 100 mg/kg."( Disposition kinetics and dosage regimen of sulfapyridine in buffalo (Bubalus bubalis).
Chaudhary, RK; Rampal, S; Srivastava, AK, 1992
)
0.8
"The clinical pharmacokinetics of enteric-coated sulphasalazine (Salazopyrin-EN) were studied after acute and chronic dosing in 20 patients with 'active' rheumatoid arthritis."( The pharmacokinetics of sulphasalazine in young and elderly patients with rheumatoid arthritis.
Ahnfelt, NO; Delargy, M; Elborn, S; Forbes, J; McDermott, B; Roberts, SD; Taggart, AJ, 1987
)
0.27
" The aim of our work was to assess the levels of the drug in blood (SASP and SP), to correlate them with undesirable effects in any, to verify their fluctuations in the dosing interval and to investigate the extent of the excretion of the drug in the children who were studied."( [Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment].
Guastavino, E; Heffes Nahmod, L; Licastro, R; Litwin, NH, 1988
)
0.52
"Miniaturised methods have been used to construct dose-response curves for the effects of inhibitory drugs on prostaglandin synthesis using individual rectal biopsies obtained from patients with ulcerative colitis."( Inhibition of prostaglandin synthetase in human rectal mucosa.
Hawkey, CJ; Lo Casto, M, 1983
)
0.27
" A pharmacokinetic comparison of polymer and SASP showed similar deliveries of 5-ASA and metabolites to the lower bowel, blood, and urine of orally dosed rats."( A polymeric drug for treatment of inflammatory bowel disease.
Brown, JP; McGarraugh, GV; Onderdonk, AB; Parkinson, TM; Wingard, RE, 1983
)
0.27
" The results showed that, although there were wide individual variations in levels after oral and rectal administration, with the same dosage the levels were far higher when the drug was given orally."( A comparison of serum concentrations of sulphasalazine and some of its metabolites after therapy by the oral or rectal route.
Arthur, M; Ashworth, M; Smith, PR; Turmer, AD, 1984
)
0.27
"A peroral dosage form was examined to deliver recombinant human granulocyte colony-stimulating factor (rhG-CSF) to the colon in beagle dogs."( Development of a colon delivery capsule and the pharmacological activity of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in beagle dogs.
Ikeda, C; Imagawa, N; Niwa, K; Takada, K; Takaya, T, 1995
)
0.29
" The total transit time was shortened to 8 days after treatment with sulphapyridine at a dosage of 450 mg kg-1 for 38-52 days."( Effects of sulphapyridine on sperm transport through the rat epididymis and contractility of the epididymal duct.
Chaturapanich, G; Pholpramool, C; Sujarit, K, 1999
)
0.3
"Cells were dosed with each compound for 24 h in the presence or absence of PMA inducer and messenger RNA (mRNA) extracted and subjected to Northern blot analysis."( Effects of sulfasalazine and its metabolites on steady state messenger RNA concentrations for inflammatory cytokines, matrix metalloproteinases, and tissue inhibitors of metalloproteinase in rheumatoid synovial fibroblasts.
Blackburn, WD; Minghetti, PP, 2000
)
0.31
" Synovial tissue explants from RA patients secreted a decreased amount of the chemokines IL-8 and growth-related gene product alpha (GROalpha) when treated with SASP over a broad range of concentrations based on the typical clinical dosage of 2 g/day."( The effect of sulfasalazine on rheumatoid arthritic synovial tissue chemokine production.
Campbell, PL; Connors, MA; Koch, AE; Volin, MV; Woodruff, DC, 2002
)
0.31
" Clear dose-response relations were determined with SIR when the short-term incubation of 4h was extended into the growth phase of the microorganisms (24 and 48 h)."( Effects of sulfonamide and tetracycline antibiotics on soil microbial activity and microbial biomass.
Beck, IC; Thiele-Bruhn, S, 2005
)
0.33
" The increment in ferrate(VI) dosage was surely favorable for SPY removal."( Removal of sulfapyridine by ferrate(VI): efficiency, influencing factors and oxidation pathway.
Deng, J; Liu, Y; Wang, H; Wang, S; Wu, H, 2019
)
0.9
" Fixed bed column experiments with Al-modified biochar packed in different dosages (250, 500 and 1000 mg) and flow rates (1, 2 and 4 mL/min) showed the dosage of 1000 mg and flow rate of 1 mL/min performed the best for the removal of both SMX and SPY from wastewater."( Fixed bed column performance of Al-modified biochar for the removal of sulfamethoxazole and sulfapyridine antibiotics from wastewater.
Chen, H; Gao, B; Huang, J; Wan, Y; Yang, Y; Zhang, Y; Zheng, Y; Zimmerman, AR, 2022
)
0.94
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
antiinfective agentA substance used in the prophylaxis or therapy of infectious diseases.
dermatologic drugA drug used to treat or prevent skin disorders or for the routine care of skin.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
substituted aniline
sulfonamide antibioticA class of sulfonamides whose members generally have bacteriostatic antibiotic properties.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (25)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency35.48130.044717.8581100.0000AID485294
Chain A, Ferritin light chainEquus caballus (horse)Potency6.30965.623417.292931.6228AID485281
Chain A, CruzipainTrypanosoma cruziPotency2.51190.002014.677939.8107AID1476
phosphopantetheinyl transferaseBacillus subtilisPotency0.63100.141337.9142100.0000AID1490
RAR-related orphan receptor gammaMus musculus (house mouse)Potency18.23820.006038.004119,952.5996AID1159521; AID1159523
AR proteinHomo sapiens (human)Potency0.40650.000221.22318,912.5098AID743036
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency33.49150.001022.650876.6163AID1224838
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency13.80290.01237.983543.2770AID1645841
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency0.35480.28189.721235.4813AID2326
GVesicular stomatitis virusPotency19.49710.01238.964839.8107AID1645842
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency0.70790.707936.904389.1251AID504333
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency10.68220.023723.228263.5986AID743223
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency25.11890.035520.977089.1251AID504332
gemininHomo sapiens (human)Potency0.63100.004611.374133.4983AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency17.78280.125912.234435.4813AID1458
Interferon betaHomo sapiens (human)Potency19.49710.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency19.49710.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency19.49710.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency19.49710.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 1Homo sapiens (human)IC50 (µMol)14.72530.00582.14107.9000AID1803142
Carbonic anhydrase 1Homo sapiens (human)Ki32.85200.00001.372610.0000AID1803136
Carbonic anhydrase 2Homo sapiens (human)IC50 (µMol)14.72530.00021.10608.3000AID1803142
Carbonic anhydrase 2Homo sapiens (human)Ki32.85200.00000.72369.9200AID1803136
Carbonic anhydrase 6Homo sapiens (human)IC50 (µMol)14.72530.02001.33175.7900AID1803142
Carbonic anhydrase 6Homo sapiens (human)Ki32.85200.00011.47109.9200AID1803136
Carbonic anhydrase 3Bos taurus (cattle)Ki32.85200.11303.88159.7100AID1803136
Protein-arginine deiminase type-4Homo sapiens (human)IC50 (µMol)10,000.00002.50004.20005.9000AID320706
Cystine/glutamate transporterHomo sapiens (human)IC50 (µMol)1,000.00000.14001.14005.0000AID622159
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (97)

Processvia Protein(s)Taxonomy
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 6Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
chromatin organizationProtein-arginine deiminase type-4Homo sapiens (human)
nucleosome assemblyProtein-arginine deiminase type-4Homo sapiens (human)
chromatin remodelingProtein-arginine deiminase type-4Homo sapiens (human)
stem cell population maintenanceProtein-arginine deiminase type-4Homo sapiens (human)
protein modification processProtein-arginine deiminase type-4Homo sapiens (human)
post-translational protein modificationProtein-arginine deiminase type-4Homo sapiens (human)
innate immune responseProtein-arginine deiminase type-4Homo sapiens (human)
glutathione metabolic processCystine/glutamate transporterHomo sapiens (human)
visual learningCystine/glutamate transporterHomo sapiens (human)
response to toxic substanceCystine/glutamate transporterHomo sapiens (human)
response to organic cyclic compoundCystine/glutamate transporterHomo sapiens (human)
L-cystine transportCystine/glutamate transporterHomo sapiens (human)
L-glutamate transmembrane transportCystine/glutamate transporterHomo sapiens (human)
ventricular system developmentCystine/glutamate transporterHomo sapiens (human)
striatum developmentCystine/glutamate transporterHomo sapiens (human)
adult behaviorCystine/glutamate transporterHomo sapiens (human)
regulation of neutrophil apoptotic processCystine/glutamate transporterHomo sapiens (human)
cellular response to oxidative stressCystine/glutamate transporterHomo sapiens (human)
glutathione transmembrane transportCystine/glutamate transporterHomo sapiens (human)
response to nicotineCystine/glutamate transporterHomo sapiens (human)
regulation of cell population proliferationCystine/glutamate transporterHomo sapiens (human)
regulation of melanin biosynthetic processCystine/glutamate transporterHomo sapiens (human)
lung alveolus developmentCystine/glutamate transporterHomo sapiens (human)
modulation of chemical synaptic transmissionCystine/glutamate transporterHomo sapiens (human)
regulation of synapse organizationCystine/glutamate transporterHomo sapiens (human)
regulation of protein transportCystine/glutamate transporterHomo sapiens (human)
response to redox stateCystine/glutamate transporterHomo sapiens (human)
limb developmentCystine/glutamate transporterHomo sapiens (human)
lens fiber cell differentiationCystine/glutamate transporterHomo sapiens (human)
platelet aggregationCystine/glutamate transporterHomo sapiens (human)
intracellular glutamate homeostasisCystine/glutamate transporterHomo sapiens (human)
L-glutamate import across plasma membraneCystine/glutamate transporterHomo sapiens (human)
negative regulation of ferroptosisCystine/glutamate transporterHomo sapiens (human)
dipeptide import across plasma membraneCystine/glutamate transporterHomo sapiens (human)
L-kynurenine transmembrane transportCystine/glutamate transporterHomo sapiens (human)
regulation of cellular response to oxidative stressCystine/glutamate transporterHomo sapiens (human)
regulation of cysteine metabolic processCystine/glutamate transporterHomo sapiens (human)
regulation of glutathione biosynthetic processCystine/glutamate transporterHomo sapiens (human)
regulation of AMPA glutamate receptor clusteringCystine/glutamate transporterHomo sapiens (human)
regulation of glutamate metabolic processCystine/glutamate transporterHomo sapiens (human)
amino acid transmembrane transportCystine/glutamate transporterHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 6Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 3Bos taurus (cattle)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein-arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
calcium ion bindingProtein-arginine deiminase type-4Homo sapiens (human)
protein bindingProtein-arginine deiminase type-4Homo sapiens (human)
identical protein bindingProtein-arginine deiminase type-4Homo sapiens (human)
histone arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
histone H3R2 arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
histone H3R8 arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
histone H3R17 arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
histone H3R26 arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
protein bindingCystine/glutamate transporterHomo sapiens (human)
cystine:glutamate antiporter activityCystine/glutamate transporterHomo sapiens (human)
L-kynurenine transmembrane transporter activityCystine/glutamate transporterHomo sapiens (human)
L-amino acid transmembrane transporter activityCystine/glutamate transporterHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular regionCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
cytosolCarbonic anhydrase 6Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusProtein-arginine deiminase type-4Homo sapiens (human)
nucleoplasmProtein-arginine deiminase type-4Homo sapiens (human)
cytosolProtein-arginine deiminase type-4Homo sapiens (human)
protein-containing complexProtein-arginine deiminase type-4Homo sapiens (human)
nucleusProtein-arginine deiminase type-4Homo sapiens (human)
cytoplasmProtein-arginine deiminase type-4Homo sapiens (human)
plasma membraneCystine/glutamate transporterHomo sapiens (human)
cell surfaceCystine/glutamate transporterHomo sapiens (human)
membraneCystine/glutamate transporterHomo sapiens (human)
brush border membraneCystine/glutamate transporterHomo sapiens (human)
microvillus membraneCystine/glutamate transporterHomo sapiens (human)
apical part of cellCystine/glutamate transporterHomo sapiens (human)
astrocyte projectionCystine/glutamate transporterHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (146)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID425632Antituberculosis activity against Mycobacterium paratuberculosis ATCC 19698 isolated from bovine assessed as minimum drug level resulting in no detectable growth at 10'6 CFU of inoculum after 56 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1211099Drug metabolism in wild-type Wistar rat assessed as metabolite to parent ratio treated with sulfasalazine at 20 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID1211135Tmax in BCRP knockout Sprague-Dawley rat treated with sulfasalazine at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID415827Half life in TNBS-induced po dosed Wistar rat colitis model assessed as assessed as release of 5-aminosalicylic acid2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Colon-specific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats.
AID320706Inhibition of PAD4 by ABPP-based assay2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors.
AID78212Tested for mean score after quantitative histological evaluation result in guinea pig1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
A polymeric drug for treatment of inflammatory bowel disease.
AID1211105Tmax in wild-type Wistar rat at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID17043Affinity for protein binding expressed as association constant in fresh rat serum1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Quantitative structure-pharmacokinetic relationships derived on antibacterial sulfonamides in rats and its comparison to quantitative structure-activity relationships.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1211104Cmax in MRP2-deficient Wistar rat at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID750784Antimicrobial activity against Salmonella typhi ATCC 23564 assessed as diameter of inhibition zone at 80 uM after 24 hrs by Kirby -Baur disc diffusion method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1211103Cmax in wild-type Wistar rat at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID750785Antimicrobial activity against Bacillus cereus MTCC 7350 after 24 hrs by broth micro serial dilution method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID25769First order rate of elimination of unchanged drug in rat1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Quantitative structure-pharmacokinetic relationships derived on antibacterial sulfonamides in rats and its comparison to quantitative structure-activity relationships.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID80567Tested for weight loss in guinea pig at 60 umol concentration of compound1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
A polymeric drug for treatment of inflammatory bowel disease.
AID453203Lipophilicity, log D of the compound2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
AID750773Antimicrobial activity against Escherichia coli ATCC 35218 after 24 hrs by broth micro serial dilution method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID22408Apparent volume of distribution was determined in rat1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Quantitative structure-pharmacokinetic relationships derived on antibacterial sulfonamides in rats and its comparison to quantitative structure-activity relationships.
AID77142Tested for cecal ulceration in necropsy at 60 umol concentration of compound1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
A polymeric drug for treatment of inflammatory bowel disease.
AID25791Overall elimination rate in rat1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Quantitative structure-pharmacokinetic relationships derived on antibacterial sulfonamides in rats and its comparison to quantitative structure-activity relationships.
AID1211123Drug metabolism in BCRP knockout Sprague-Dawley rat assessed as metabolite to parent ratio treated with sulfasalazine at 20 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID750777Antimicrobial activity against Pseudomonas aeruginosa ATCC 15499 after 24 hrs by broth micro serial dilution method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID1211102AUC (infinity) in MRP2-deficient Wistar rat at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1211130Cmax in MDR1A knockout Sprague-Dawley rat treated with sulfasalazine at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID1211131Cmax in BCRP knockout Sprague-Dawley rat treated with sulfasalazine at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID1211140Half life in MRP2 knockout Sprague-Dawley rat treated with sulfasalazine at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID442505Inhibition of PTK2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis, antitumor activity and molecular docking study of novel sulfonamide-Schiff's bases, thiazolidinones, benzothiazinones and their C-nucleoside derivatives.
AID1211128AUC (infinity) in MRP2 knockout Sprague-Dawley rat treated with sulfasalazine at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID1211138Half life in MDR1A knockout Sprague-Dawley rat treated with sulfasalazine at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID425630Antituberculosis activity against Mycobacterium paratuberculosis ATCC 19698 isolated from bovine assessed as lowest drug level producing inhibition at 10'6 CFU of inoculum by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID1211132Cmax in MRP2 knockout Sprague-Dawley rat treated with sulfasalazine at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID750776Antimicrobial activity against Escherichia coli ATCC 35218 assessed as diameter of inhibition zone at 80 uM after 24 hrs by Kirby -Baur disc diffusion method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID16091Total clearance from the body in rat1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Quantitative structure-pharmacokinetic relationships derived on antibacterial sulfonamides in rats and its comparison to quantitative structure-activity relationships.
AID1211108Half life in MRP2-deficient Wistar rat at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID750781Antimicrobial activity against Salmonella typhi ATCC 23564 after 24 hrs by broth micro serial dilution method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID453204Permeability in human skin after 48 hrs by Franz cell permeability assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
AID1211126AUC (infinity) in MDR1A knockout Sprague-Dawley rat treated with sulfasalazine at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID1211106Tmax in MRP2-deficient Wistar rat at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1211133Tmax in wild-type Sprague-Dawley rat treated with sulfasalazine at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID25817PKa value was measured1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Structure-activity relationships in dihydropteroate synthase inhibition by sulfanilamides. Comparison with the antibacterial activity.
AID1211134Tmax in MDR1A knockout Sprague-Dawley rat treated with sulfasalazine at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID55867Inhibition of Escherichia coli (K12J53) Dihydopteroate synthase.1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Structure-activity relationships in dihydropteroate synthase inhibition by sulfanilamides. Comparison with the antibacterial activity.
AID1211124Drug metabolism in MRP2 knockout Sprague-Dawley rat assessed as metabolite to parent ratio treated with sulfasalazine at 20 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1211107Half life in wild-type Wistar rat at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID750780Antimicrobial activity against Pseudomonas aeruginosa ATCC 15499 assessed as diameter of inhibition zone at 80 uM after 24 hrs by Kirby -Baur disc diffusion method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID77141Tested for cecal ulceration in diarrhea at 60 umol concentration of compound1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
A polymeric drug for treatment of inflammatory bowel disease.
AID1211139Half life in BCRP knockout Sprague-Dawley rat treated with sulfasalazine at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID425629Antituberculosis activity against Mycobacterium paratuberculosis ATCC 19698 isolated from bovine assessed as effect on average time to detection of growth at 10'5 CFU of inoculum by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID1211122Drug metabolism in MDR1A knockout Sprague-Dawley rat assessed as metabolite to parent ratio treated with sulfasalazine at 20 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID750789Antimicrobial activity against Staphylococcus aureus ATCC 11632 after 24 hrs by broth micro serial dilution method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID1211127AUC (infinity) in BCRP knockout Sprague-Dawley rat treated with sulfasalazine at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID425631Antituberculosis activity against Mycobacterium paratuberculosis ATCC 19698 isolated from bovine assessed as lowest drug level producing inhibition at 10'6 CFU of inoculum by agar counting method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID1211100Drug metabolism in MRP2-deficient Wistar rat assessed as metabolite to parent ratio treated with sulfasalazine at 20 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID1211129Cmax in wild-type Sprague-Dawley rat treated with sulfasalazine at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID25445Half life in rat1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Quantitative structure-pharmacokinetic relationships derived on antibacterial sulfonamides in rats and its comparison to quantitative structure-activity relationships.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID750792Antimicrobial activity against Staphylococcus aureus ATCC 11632 assessed as diameter of inhibition zone at 80 uM after 24 hrs by Kirby -Baur disc diffusion method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID1211125AUC (infinity) in wild-type Sprague-Dawley rat treated with sulfasalazine at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID1211101AUC (infinity) in wild-type Wistar rat at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1211121Drug metabolism in wild-type Sprague-Dawley rat assessed as metabolite to parent ratio treated with sulfasalazine at 20 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID750788Antimicrobial activity against Bacillus cereus MTCC 7350 assessed as diameter of inhibition zone at 80 uM after 24 hrs by Kirby -Baur disc diffusion method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID16086Metabolic clearance from the body in rat1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Quantitative structure-pharmacokinetic relationships derived on antibacterial sulfonamides in rats and its comparison to quantitative structure-activity relationships.
AID16088Renal clearance from the body in rat1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Quantitative structure-pharmacokinetic relationships derived on antibacterial sulfonamides in rats and its comparison to quantitative structure-activity relationships.
AID55868In vitro inhibition of Escherichia coli (K12J53) growth.1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Structure-activity relationships in dihydropteroate synthase inhibition by sulfanilamides. Comparison with the antibacterial activity.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID25105Acid dissociation constant1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Quantitative structure-pharmacokinetic relationships derived on antibacterial sulfonamides in rats and its comparison to quantitative structure-activity relationships.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID622159Inhibition of xc-cystine-glutamate antiporter-mediated cystine uptake in human U87 cells using L-[14C]cystine as substrate after 15 mins by liquid scintillation counting2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Inhibition of xc⁻ transporter-mediated cystine uptake by sulfasalazine analogs.
AID1211136Tmax in MRP2 knockout Sprague-Dawley rat treated with sulfasalazine at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID425628Antituberculosis activity against Mycobacterium paratuberculosis ATCC 19698 isolated from bovine assessed as effect on average time to detection of growth at >10'2 CFU of inoculum by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID1530048Inhibition of Streptococcus pyogenes SrtA deltaN81 mutant expressed in Escherichia coli BL21(DE3) at 100 uM using Abz-LPETA-Dap(Dnp) as substrate preincubated for 10 mins followed by substrate addition measured every min for 2.5 hrs by fluorimetric assay 2019European journal of medicinal chemistry, Jan-01, Volume: 161Identification of potential antivirulence agents by substitution-oriented screening for inhibitors of Streptococcus pyogenes sortase A.
AID77143Tested for cecal ulceration with mortality at 60 umol concentration of compound1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
A polymeric drug for treatment of inflammatory bowel disease.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1211137Half life in wild-type Sprague-Dawley rat treated with sulfasalazine at 20 mg/kg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1803136CA Activity Assay from Article 10.3109/14756366.2011.621122: \\Carbonic anhydrase inhibitors: inhibition of human and bovine isoenzymes by benzenesulphonamides, cyclitols and phenolic compounds.\\2012Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 27, Issue:6
Carbonic anhydrase inhibitors: inhibition of human and bovine isoenzymes by benzenesulphonamides, cyclitols and phenolic compounds.
AID1803142Esterase Activity Assay from Article 10.3109/14756366.2011.617745: \\Sulfapyridine-like benzenesulfonamide derivatives as inhibitors of carbonic anhydrase isoenzymes I, II and VI.\\2012Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 27, Issue:6
Sulfapyridine-like benzenesulfonamide derivatives as inhibitors of carbonic anhydrase isoenzymes I, II and VI.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (454)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990244 (53.74)18.7374
1990's79 (17.40)18.2507
2000's42 (9.25)29.6817
2010's65 (14.32)24.3611
2020's24 (5.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.88 (24.57)
Research Supply Index6.25 (2.92)
Research Growth Index4.47 (4.65)
Search Engine Demand Index78.74 (26.88)
Search Engine Supply Index1.99 (0.95)

This Compound (48.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials30 (6.16%)5.53%
Reviews28 (5.75%)6.00%
Case Studies42 (8.62%)4.05%
Observational0 (0.00%)0.25%
Other387 (79.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]